Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: joint analysis of MILES-3 and MILES-4 randomised phase 3 trials

Chemotherapy remains a cornerstone of advanced lung cancer treatment even after some target based agents have been developed and, more recently, immune checkpoint inhibitors are proving effective. A low rate of patients (about 20%), indeed, is eligible for target based agents, and immune checkpoint inhibitors do actually represent only one possible line of treatment (first or second depending on the drug and the PDL1 expression) and do not yet promise to let chemotherapy disappear from the clinical scenario of lung cancer.

Source: Lung Cancer - May 8, 2019 Category: Cancer & Oncology Authors: Alessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, Andrea Luciani, Luigi Cavanna, Laura Bonanno, Virginio Filipazzi, Silvana Leo, Saverio Cinieri, Floriana Morgillo, Marco Angelo Burgio, Domenica Ferrara, Francesco Rosetti, Roberto Bianco, Fabri Source Type: research